Grace Therapeutics raises approximately $4.0 million through common warrant exercises following FDA's acceptance of its New Drug Application for GTx-104.

PUBLIC · GRCEOct 23, 2025

Amount Raised

$4 Million

Round Type

Funding Round

LavalBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Grace Therapeutics, Inc. has secured approximately $4.0 million in additional funding through exercises of common warrants. The funding follows the FDA's acceptance for review of the Company's New Drug Application for GTx-104. The company issued 1,345,464 new shares of common stock at an exercise price of $3.003 per share

Who else raised in Therapeutics and Pharmaceutical around the same time

Companies in the same sectors as Acasti that raised within 45 days of this round, from Fundz verified event records.

Minerva Neurosciences raised $200M (Funding Round) on October 21, 2025.
ISOThrive raised $8.1M on October 10, 2025.
TORL BioTherapeutics raised $96M (Series C) on October 7, 2025.
Santhera Pharmaceuticals raised $21M (Funding Round) on September 23, 2025.
Axoltis Pharma raised $21M (Series A) on December 2, 2025.
Azora Therapeutics, Inc. (DE) raised $4.3M on November 28, 2025.

Who to call at Acasti, and when

A new round usually means Acasti is about to hire and buy. The teams that reach out first get the meeting.

An alert the day Acasti raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Acasti, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Acasti. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Acasti

Location

2572 boul. Daniel-Johnson

Laval, Quebec, Canada

About

Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company’s novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery – all which could help to increase treatment compliance and improve patient outcomes. The Company is focused on well-understood diseases that are poorly served by available therapies or have no approved therapies. Acasti is initially targeting three underserved orphan diseases - Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN) – all with sizable patient populations and significant market opportunity. The Company’s three lead clinical assets have all been granted Orphan Drug Designation by the FDA providing seven years of marketing exclusivity post-launch in the United States and are protected by over 40 granted and pending patents.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Acasti raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans

Related People

1 contact

Verified contacts5 people are listed at Acasti. We don't have their email yet.See plans and pricing

Predictive Intelligence

Strategic

ML-powered predictions for Acasti's next move

See what Strategic adds

Acasti raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

Show me how a sales rep uses this Or see plans and pricing →

5 screens from a live account. No signup.